Background Opioid dependence is associated with substantial health and social burdens,
and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for …

Importance In 2017, the US Food and Drug Administration (FDA) approved a monthly
injectable form of buprenorphine, extended-release buprenorphine; published data show …

Importance Although HIV preexposure prophylaxis (PrEP) implementation among persons
who inject drugs has been inadequate, national HIV monitoring programs do not include …

Introduction Adherence to daily oral antiretroviral therapy (ART) and regular clinic
appointments can be challenging for individuals who experience adverse social …

Efforts to develop and test vaccines targeting OUD are based on a foundation of preclinical
work and close collaboration between preclinical and clinical researchers. Efforts to learn …

Importance Serious injection-related infections (SIRIs) cause significant morbidity and
mortality. Medication for opioid use disorder (MOUD) improves outcomes but is underused …

We examine how extended-release buprenorphine depot (BUP-XR) is put to use and made
to work in implementation practices, attending to how care practices are challenged and …

Background: The association between cost-sharing and receipt of medication for opioid use
disorder (MOUD) is unknown. Methods: We constructed a cohort of 10,513 commercially …

Importance Stimulant medication use is common among individuals receiving
buprenorphine for opioid use disorder (OUD). Associations between prescription stimulant …

As the opioid overdose epidemic escalates, there is an urgent need for treatment
innovations to address both patient and clinician barriers when initiating buprenorphine in …